8-K: Applied Therapeutics Acquired by Cycle Group for $14.3M

Applied Therapeutics, Inc. has been acquired by Cycle Group Holdings Limited for approximately $14.3 million, with shareholders receiving cash and contingent value rights.

Summary

• The tender offer for Applied Therapeutics, Inc. (the Company) was completed, with 79,518,606 shares, representing approximately 51.56% of total outstanding shares, validly tendered.
• The merger was consummated on February 3, 2026, resulting in Applied Therapeutics becoming an indirect wholly-owned subsidiary of Cycle Group Holdings Limited (Parent).
• Shareholders received $0.088 per share in cash and one non-tradeable Contingent Value Right (CVR) per share.
• CVRs provide a contractual right to receive up to $0.40 per CVR plus a pro rata portion of any Closing Cash Payment between $500,000 and $1,500,000, upon achievement of specified milestones.
• The aggregate consideration paid by the Purchaser in the Offer and Merger was approximately $14.3 million.
• In-the-money Company Stock Options and Restricted Stock Units (RSUs) automatically vested and were cancelled, with holders receiving cash (equal to the Closing Amount minus exercise price for options, or Closing Amount for RSUs) and one CVR per share.
• Out-of-the-money Company Stock Options and certain Other Legacy Warrants were cancelled without consideration.
• Common Stock Warrants and Pre-Funded Warrants were cancelled and converted into a cash right equal to their Black Scholes Value.
• Legacy Warrants entitle holders to the Merger Consideration upon exercise.
• The Company will be required to repay an Unsecured Promissory Note to Parent, along with accrued interest, ten days after the closing date.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative event for existing public shareholders due to the very low cash offer, cancellation of out-of-the-money equity, and the illiquid, uncertain nature of the CVRs, effectively marking a distressed exit from the public market.

Positives

• Shareholders received a cash payment of $0.088 per share, providing immediate liquidity for a portion of their investment.
• Shareholders also received a non-tradeable Contingent Value Right (CVR) per share, offering potential future upside of up to $0.40 per CVR plus a pro rata share of certain closing cash amounts.
• In-the-money stock options and restricted stock units vested and converted to cash and CVRs, providing value to equity holders.
• The acquisition provides a definitive exit for public shareholders, transitioning the company to private ownership.

Negatives

• Applied Therapeutics, Inc. will be delisted from Nasdaq and deregistered, ceasing to be a publicly traded company.
• Out-of-the-money stock options and certain Other Legacy Warrants were cancelled without any consideration, resulting in a complete loss for those holders.
• The Contingent Value Rights (CVRs) are non-tradeable, limiting liquidity and making their future value uncertain and dependent on specific milestones and cash conditions.
• The cash component of the offer price ($0.088 per share) is relatively low, potentially representing a significant loss for many investors.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and entirely dependent on the achievement of specified milestones and the existence of Closing Cash, with no guarantee of any future payments.
• CVRs are non-tradeable, meaning holders cannot sell them for immediate liquidity or price discovery.
• The Company's reporting obligations under the Exchange Act will be suspended, reducing transparency and access to financial information for former public shareholders.

Future Outlook

The Company will transition to a private entity, and its public reporting obligations will cease. The future value for former shareholders holding CVRs is entirely dependent on the achievement of specified milestones and the existence of Closing Cash as defined in the CVR Agreement, which is uncertain.

Management Comments

• James Harrison became the President of the Company.
• Andrea Reiner became the Secretary of the Company.

Industry Context

StockSavvy.ai notes that this acquisition reflects a trend in the biotechnology and pharmaceutical sectors where smaller, often struggling, public companies are taken private by larger entities or private equity firms. This can provide an exit for public shareholders, albeit sometimes at a low valuation, while allowing the acquiring company to integrate assets or intellectual property without the burdens of public reporting. The use of CVRs is a common mechanism in biotech acquisitions to bridge valuation gaps and share future upside potential, particularly for clinical-stage assets.

Comparison to Industry Standards

• The cash offer of $0.088 per share, coupled with a non-tradeable CVR, suggests a low valuation for Applied Therapeutics, Inc. compared to typical biotech acquisitions, which often involve higher premiums or more liquid contingent payments.
• For example, recent biotech acquisitions like Pfizer's acquisition of Seagen for $43 billion or Merck's acquisition of Prometheus Biosciences for $10.8 billion involved significant cash premiums and immediate value for shareholders, contrasting with the low cash component and illiquid CVR structure seen here.
• While the CVR structure itself is common in biotech, the low cash base indicates an acquisition of a distressed or low-value asset.

Management Changes

Corporate Governance

Related Party Transactions

• Parent provided Purchaser with funds from its cash on hand to fund the Offer and Merger.
• The Company will repay an Unsecured Promissory Note, dated December 11, 2025, to Parent, along with accrued interest, ten days after the closing date.

Stakeholder Impact

• Shareholders: Received $0.088 cash per share and one non-tradeable CVR per share. Out-of-the-money option/warrant holders received no consideration. Loss of public market liquidity and transparency.
• Employees (with equity): In-the-money stock options and RSUs vested and converted to cash and CVRs. Out-of-the-money options were cancelled.
• Management/Directors: Significant changes in the Board of Directors and officer positions, with previous directors and officers resigning and new ones appointed by the acquiring Parent.
• Creditors: The Company will repay an Unsecured Promissory Note to Parent, indicating a change in its debt structure and obligations.

Next Steps

• Nasdaq will suspend trading of the Shares and file Form 25 to delist and deregister the Shares.
• The Company intends to file Form 15 with the SEC to suspend its reporting obligations under the Exchange Act.
• The Company will be required to repay the Unsecured Promissory Note to Parent ten days after the closing date (February 3, 2026).
• CVR holders will receive payments upon achievement of specified milestones and existence of Closing Cash, in accordance with the CVR Agreement.

Key Dates

Recommendation

The company has been acquired and delisted, meaning public shares no longer exist. For any remaining public shareholders (e.g., those who didn't tender), the stock is effectively worthless as a publicly traded security. The cash consideration was very low, and the CVRs are illiquid and speculative. This is a definitive exit for public investors, and any remaining shares should be considered a 'strong sell' if they could even be traded, or simply a recognition of the completed transaction.

Keywords

Applied Therapeutics, Cycle Group Holdings, Merger, Acquisition, Tender Offer, Delisting, Contingent Value Rights, CVR, Biotechnology, Pharmaceutical, Corporate Action, APLT, Nasdaq